神经科学抗体及检测市场－全球产业规模、份额、趋势、机会及预测（依产品、技术、应用、最终用户、地区及竞争格局划分），2021-2031年

全球神经科学抗体和检测市场预计将从 2025 年的 46.4 亿美元成长到 2031 年的 79.3 亿美元，复合年增长率达到 9.34%。

这些抗体和检测方法是用于检测、定量和分析神经系统内特定蛋白质和细胞标靶的重要专业生化工具，有助于我们了解神经元功能和病理。推动这一市场发展的主要因素是神经退化性疾病发生率的上升，这增加了对广泛开展生物标记研究以支持诊断和治疗方法开发的需求。因此，对药物研发的大量投资正在推动对检验的检测工具的需求，阿兹海默症协会的估计也印证了这一趋势：到2025年，将有720万65岁及以上的美国人患有老年痴呆症失智症。

然而，抗体特异性和可重复性方面持续存在的挑战严重阻碍了市场扩张。试剂品质的差异常常导致实验结果不一致和资源浪费，促使研究人员要求更严格的检验标准。这些品管方面的挑战使可靠诊断检测方法的开发变得复杂，并减缓了新型试剂的商业性化应用，因为科学界仍在努力确保这些工具在其实验流程中的可靠性。

市场驱动因素

全球神经退化性疾病疾病和神经系统疾病的日益普及是推动神经科学抗体和检测方法需求成长的主要因素。随着中风、偏头痛和失智症等疾病负担的加重，科学界越来越依赖高特异性试剂来绘製神经通路图谱并验证病理标靶。这场日益严峻的健康危机已将抗体研发的重点转移到检验与中枢神经系统功能障碍相关的、定义不明确的蛋白质聚集体和发炎标记。根据《柳叶刀神经病学》2024年3月刊报道，2021年全球约有34亿人患有神经系统疾病，凸显了提高诊断准确性的至关重要性。

在疫情压力之外，製药和生技公司研发投入的激增也积极推动了市场成长。产业领导企业正透过策略性收购拓展其神经科学产品线，而这些收购高度依赖先进的侦测检验。例如，BioPharm International在2024年8月报道称，艾伯维(AbbVie)以87亿美元完成了对Cellevelle Therapeutics的收购，以增强其神经科学产品组合，这表明该公司在该领域投入了大量资金。这种投资环境直接推动了试剂消耗，因为检验的工具对于临床成功至关重要。 Technology Networks在2024年1月报告称，美国FDA在前一年核准了9种新型神经系统药物，反映了加强研究的实际成果。

市场挑战

抗体特异性和可重复性持续不足严重阻碍了全球神经科学抗体和检测市场的发展。这个品管难题导致实验结果出现显着差异，使研究人员对市售试剂的可靠性产生质疑。当抗体无法与其标靶分子结合或与非标靶蛋白发生交叉反应时，会导致数据不一致和结论错误。因此，实验室在信任新产品之前，必须投入大量资金和时间进行严格的内部检验。这种营运负担会延长采购週期，并抑制新检测方法的应用，因为最终用户会优先考虑风险规避而非实验扩展。

这个问题的严重性直接阻碍了市场收入的成长。美国国家动物实验替代、补救和减少中心 (NC3Rs) 在 2024 年的一项评估中发现，在针对 65 种神经科学相关蛋白测试的 614 种市售抗体中，超过 50% 的抗体在至少一个主要应用领域的表征实验中失败。如此高的失败率需要昂贵的检验流程，这限制了研究机构采购和使用这些工具的速度，最终降低了整体市场容量。

市场趋势

将人工智慧 (AI) 应用于抗体发现和设计，正从根本上改变全球神经科学抗体和检测市场，满足提高试剂特异性和加速研发的关键需求。传统的融合瘤检测耗时且结果易受变异性影响，而 AI 驱动的平台则利用生成演算法In Silico模拟预测最佳结合结构。这项技术变革使得针对神经系统中难成药标靶的抗体能够精准设计，从而显着减轻研究人员的检验负担。根据《Contract Pharma》（2025 年 2 月号）报道，Harbour BioMed 和 Insilico Medicine 已达成策略合作，将各自专有的抗体平台与先进的 AI 技术相结合，以专门解决神经科学领域尚未满足的需求。这标誌着传统筛检方法的突破以及计算设计的广泛应用。

同时，用于诊断神经退化性疾病的血液生物标记的出现，正在该领域催生一个全新的、高容量的细分市场。传统上，准确诊断依赖昂贵的PET扫描和侵入性的脑脊髓液采样，这限制了患者的就诊量和重复检测。如今，市场正转向基于血浆的免疫检测，这种分析方法能够灵敏地检测磷酸化Tau和β-淀粉样蛋白等病理蛋白，从而使早期检测工具得以普及。根据《英国医学杂誌》（BMJ）2025年5月刊报道，美国食品药物管理局（FDA）核准了首个用于诊断55岁及以上患者阿兹海默症的血液检测产品Lumipulse。这标誌着监管领域的一个重要里程碑，有助于专业检测套组的大规模生产，并将神经科学诊断应用于临床实践。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球神经科学抗体及检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（耗材（试剂、抗体、检测试剂盒）、设备（微孔盘读数仪、免疫检测分析仪等））
  • 按技术（临床化学、免疫化学、分子诊断等）
  • 依应用领域（药物发现与开发、研究、体外诊断）
  • 按最终用户划分（医院和诊断中心、製药和生物技术公司、学术和研究机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美神经科学抗体及检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲神经科学抗体及检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区神经科学抗体及检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲神经科学抗体和检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲神经科学抗体及检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球神经科学抗体及检测市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abnova Corp.
• Bio-Rad Laboratories Inc.
• Biosensis Pty Ltd.
• BMG LABTECH GmbH
• Cell Signaling Technology Inc.
• Chemie Brunschwig AG
• Elabscience Bionovation Inc.
• Enzo Biochem Inc.
• F. Hoffmann La Roche Ltd.
• GenScript Biotech Corp.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Neuroscience Antibodies & Assays Market is projected to expand from USD 4.64 Billion in 2025 to USD 7.93 Billion by 2031, achieving a CAGR of 9.34%. These antibodies and assays are specialized biochemical tools essential for detecting, quantifying, and analyzing specific proteins and cellular targets within the nervous system, thereby facilitating the understanding of neural function and pathology. The primary catalyst for this market is the rising incidence of neurodegenerative diseases, which drives the need for extensive biomarker research to support diagnosis and therapeutic development. Consequently, significant investments in pharmaceutical research are boosting the demand for validated detection tools, a trend underscored by the Alzheimer's Association's estimate that 7.2 million Americans aged 65 and older will be living with Alzheimer's dementia in 2025.

However, market expansion is significantly hindered by persistent challenges regarding antibody specificity and reproducibility. Inconsistent reagent quality often leads to experimental variability and wasted resources, prompting researchers to demand stricter validation standards. This quality control obstacle complicates the development of reliable diagnostic assays and delays the commercial adoption of novel reagents, as the scientific community faces difficulties in ensuring the reliability of these tools within their experimental workflows.

Market Driver

The increasing global prevalence of neurodegenerative and neurological disorders acts as the primary force driving the demand for neuroscience antibodies and assays. As the burden of conditions such as stroke, migraine, and dementia intensifies, the scientific community increasingly relies on high-specificity reagents to map neural pathways and validate pathological targets. This escalating health crisis has shifted the focus of antibody development toward identifying obscure protein aggregates and inflammatory markers associated with central nervous system dysfunction. According to The Lancet Neurology in March 2024, neurological conditions affected approximately 3.4 billion individuals worldwide in 2021, highlighting the critical necessity for diagnostic precision.

Parallel to this epidemiological pressure, a surge in R&D expenditure by pharmaceutical and biotechnology companies is aggressively fueling market growth. Industry leaders are allocating capital to expand their neuroscience pipelines, frequently through strategic acquisitions that rely heavily on advanced assay validation. For instance, BioPharm International reported in August 2024 that AbbVie finalized an $8.7 billion acquisition of Cerevel Therapeutics to strengthen its neuroscience portfolio, demonstrating the high financial stakes in this sector. This investment environment directly supports reagent consumption, as validated tools are essential for clinical success; Technology Networks noted in January 2024 that the US FDA approved nine novel neurology drugs in the preceding year, reflecting the tangible outcomes of this increased research intensity.

Market Challenge

The persistent lack of antibody specificity and reproducibility significantly impedes the Global Neuroscience Antibodies & Assays Market. This quality control issue creates substantial experimental variability, compelling researchers to question the reliability of commercial reagents. When antibodies fail to bind their intended targets or cross-react with non-target proteins, it leads to irreproducible data and false conclusions. Consequently, laboratories are forced to divert significant capital and time toward rigorous internal validation before they can trust new products, an operational burden that slows the purchasing cycle and discourages the adoption of novel assays as end-users prioritize risk mitigation over experimental expansion.

The magnitude of this issue creates a direct bottleneck for market revenue. According to the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), in 2024, an evaluation revealed that greater than 50% of 614 commercial antibodies tested against 65 neuroscience-related proteins failed characterization experiments in at least one key application. Such high failure rates necessitate expensive verification processes that restrict the speed at which research institutions can procure and utilize these tools, ultimately reducing overall market throughput.

Market Trends

The integration of Artificial Intelligence in antibody discovery and design is fundamentally reshaping the Global Neuroscience Antibodies & Assays Market by addressing the critical need for enhanced reagent specificity and accelerated development. Unlike traditional hybridoma methods which are time-consuming and prone to variability, AI-driven platforms leverage generative algorithms to predict optimal binding structures in silico before wet-lab synthesis. This technological shift allows for the precise engineering of antibodies against difficult-to-drug targets within the nervous system, significantly reducing the validation burden on researchers. According to Contract Pharma, February 2025, Harbour BioMed and Insilico Medicine entered a strategic partnership to combine proprietary antibody platforms with advanced AI capabilities to specifically address unmet medical needs in neuroscience, indicating a departure from standard screening towards the widespread adoption of computational design.

Concurrently, the emergence of blood-based biomarkers for neurodegenerative diagnostics is creating a new, high-volume segment within the sector. Historically, accurate diagnosis relied on expensive PET scans or invasive cerebrospinal fluid collection, restricting patient throughput and repeat testing. The market is now pivoting toward plasma-based immunoassays that can detect pathological proteins such as phosphorylated tau and beta-amyloid with high sensitivity, democratizing access to early detection tools. According to The BMJ, May 2025, the US FDA approved the first blood test, Lumipulse, for diagnosing Alzheimer's disease in patients aged over 55, signifying a major regulatory milestone that drives the mass production of specialized assay kits and moves neuroscience diagnostics into broader clinical practice.

Key Market Players

• Abnova Corp.
• Bio-Rad Laboratories Inc.
• Biosensis Pty Ltd.
• BMG LABTECH GmbH
• Cell Signaling Technology Inc.
• Chemie Brunschwig AG
• Elabscience Bionovation Inc.
• Enzo Biochem Inc.
• F. Hoffmann La Roche Ltd.
• GenScript Biotech Corp.

Report Scope

In this report, the Global Neuroscience Antibodies & Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuroscience Antibodies & Assays Market, By Product

• Consumables (Reagents, Antibodies, Assay Kits)
• Instruments (Microplate Readers, Immunoassay Analyzers, Others)

Neuroscience Antibodies & Assays Market, By Technology

• Clinical Chemistry
• Immunochemistry
• Molecular Diagnostics
• others

Neuroscience Antibodies & Assays Market, By Application

• Drug Discovery & Development
• Research
• In Vitro Diagnostics

Neuroscience Antibodies & Assays Market, By End user

• Hospitals & Diagnostics Centers
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• others

Neuroscience Antibodies & Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuroscience Antibodies & Assays Market.

Available Customizations:

Global Neuroscience Antibodies & Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuroscience Antibodies & Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables (Reagents, Antibodies, Assay Kits), Instruments (Microplate Readers, Immunoassay Analyzers, others))
  • 5.2.2. By Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, others)
  • 5.2.3. By Application (Drug Discovery & Development, Research, In Vitro Diagnostics)
  • 5.2.4. By End user (Hospitals & Diagnostics Centers, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Neuroscience Antibodies & Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuroscience Antibodies & Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Neuroscience Antibodies & Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Neuroscience Antibodies & Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End user

7. Europe Neuroscience Antibodies & Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuroscience Antibodies & Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End user
  • 7.3.2. France Neuroscience Antibodies & Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Neuroscience Antibodies & Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Neuroscience Antibodies & Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Neuroscience Antibodies & Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End user

8. Asia Pacific Neuroscience Antibodies & Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neuroscience Antibodies & Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End user
  • 8.3.2. India Neuroscience Antibodies & Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Neuroscience Antibodies & Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Neuroscience Antibodies & Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Neuroscience Antibodies & Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End user

9. Middle East & Africa Neuroscience Antibodies & Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neuroscience Antibodies & Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Neuroscience Antibodies & Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Neuroscience Antibodies & Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End user

10. South America Neuroscience Antibodies & Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neuroscience Antibodies & Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Neuroscience Antibodies & Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Neuroscience Antibodies & Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neuroscience Antibodies & Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abnova Corp.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bio-Rad Laboratories Inc.
• 15.3. Biosensis Pty Ltd.
• 15.4. BMG LABTECH GmbH
• 15.5. Cell Signaling Technology Inc.
• 15.6. Chemie Brunschwig AG
• 15.7. Elabscience Bionovation Inc.
• 15.8. Enzo Biochem Inc.
• 15.9. F. Hoffmann La Roche Ltd.
• 15.10. GenScript Biotech Corp.

16. Strategic Recommendations

17. About Us & Disclaimer